Cargando…

Highly Selective PPARα (Peroxisome Proliferator‐Activated Receptor α) Agonist Pemafibrate Inhibits Stent Inflammation and Restenosis Assessed by Multimodality Molecular‐Microstructural Imaging

BACKGROUND: New pharmacological approaches are needed to prevent stent restenosis. This study tested the hypothesis that pemafibrate, a novel clinical selective PPARα (peroxisome proliferator‐activated receptor α) agonist, suppresses coronary stent‐induced arterial inflammation and neointimal hyperp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Iwata, Hiroshi, Osborn, Eric A., Ughi, Giovanni J., Murakami, Kentaro, Goettsch, Claudia, Hutcheson, Joshua D., Mauskapf, Adam, Mattson, Peter C., Libby, Peter, Singh, Sasha A., Matamalas, Joan, Aikawa, Elena, Tearney, Guillermo J., Aikawa, Masanori, Jaffer, Farouc A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8751880/ https://www.ncbi.nlm.nih.gov/pubmed/34632804 http://dx.doi.org/10.1161/JAHA.121.020834

Ejemplares similares

The Peroxisome Proliferator-Activated Receptor α (PPARα) Agonist Pemafibrate Protects against Diet-Induced Obesity in Mice
por: Araki, Masaya, et al.
Publicado: (2018)

Enrichment of calcifying extracellular vesicles using density-based ultracentrifugation protocol
por: Hutcheson, Joshua D., et al.
Publicado: (2014)

3D cellular-resolution imaging in arteries using few-mode interferometry
por: Yin, Biwei, et al.
Publicado: (2019)

Systems Approach to Discovery of Therapeutic Targets for Vein Graft Disease: PPARα Pivotally Regulates Metabolism, Activation, and Heterogeneity of Macrophages and Lesion Development
por: Decano, Julius L., et al.
Publicado: (2021)

Gene Expression Profiles Induced by a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα) Pemafibrate
por: Sasaki, Yusuke, et al.
Publicado: (2019)

Clinically Relevant Dose of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα), Lowers Serum Triglyceride Levels by Targeting Hepatic PPARα in Mice
por: Zhang, Zhe, et al.
Publicado: (2022)

Effects of a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator K-877 (Pemafibrate) on Postprandial hyperlipidemia
por: Fujioka, Yoshio
Publicado: (2018)

Marked effects of novel selective peroxisome proliferator-activated receptor α modulator, pemafibrate in severe hypertriglyceridemia: preliminary report
por: Iitake, Chie, et al.
Publicado: (2020)

Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα) in the Metabolic Syndrome: Is Pemafibrate Light at the End of the Tunnel?
por: Fruchart, Jean-Charles, et al.
Publicado: (2021)

Pemafibrate, a potent selective peroxisome proliferator-activated receptor α modulator, a promising novel treatment for ischemic retinopathy?
por: Lee, Deokho, et al.
Publicado: (2022)

Effect of fenofibrate and selective PPARα modulator (SPPARMα), pemafibrate on KATP channel activity and insulin secretion
por: Kitamura, Shigeki, et al.
Publicado: (2023)

Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment
por: Yokote, Koutaro, et al.
Publicado: (2019)

Effects of a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator, Pemafibrate, on Metabolic Parameters: A Retrospective Longitudinal Study
por: Yanai, Hidekatsu, et al.
Publicado: (2022)

A Novel Selective PPARα Modulator (SPPARMα), K-877 (Pemafibrate), Attenuates Postprandial Hypertriglyceridemia in Mice
por: Sairyo, Masami, et al.
Publicado: (2018)

Clinical Applications of a Novel Selective PPARα Modulator, Pemafibrate, in Dyslipidemia and Metabolic Diseases
por: Yamashita, Shizuya, et al.
Publicado: (2019)

Erratum:A Novel Selective PPARα Modulator (SPPARMα), K-877 (Pemafibrate), Attenuates Postprandial Hypertriglyceridemia in Mice
por: Sairyo, Masami, et al.
Publicado: (2018)

Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator‐activated receptor α modulator (SPPARMα), versus placebo in patients with non‐alcoholic fatty liver disease
por: Nakajima, Atsushi, et al.
Publicado: (2021)

Paclitaxel Drug-Coated Balloon Angioplasty Suppresses Progression and Inflammation of Experimental Atherosclerosis in Rabbits
por: Chowdhury, Mohammed M., et al.
Publicado: (2020)

Novel Selective PPARα Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and Atherosclerosis †
por: Yamashita, Shizuya, et al.
Publicado: (2023)

Effects of a novel selective peroxisome proliferator‐activated receptor‐α modulator, pemafibrate, on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance
por: Matsuba, Ikuro, et al.
Publicado: (2018)

Pemafibrate, A Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator, Reduces Plasma Eicosanoid Levels and Ameliorates Endothelial Dysfunction in Diabetic Mice
por: Suto, Kumiko, et al.
Publicado: (2021)

Genesis and growth of extracellular vesicle-derived microcalcification in atherosclerotic plaques
por: Hutcheson, Joshua D., et al.
Publicado: (2016)

Functional and Structural Insights into Human PPARα/δ/γ Subtype Selectivity of Bezafibrate, Fenofibric Acid, and Pemafibrate
por: Honda, Akihiro, et al.
Publicado: (2022)

Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα): Pooled Analysis of Phase 2 and 3 Studies in Dyslipidemic Patients with or without Statin Combination
por: Yamashita, Shizuya, et al.
Publicado: (2019)

Sortilin enhances fibrosis and calcification in aortic valve disease by inducing interstitial cell heterogeneity
por: Iqbal, Farwah, et al.
Publicado: (2023)

Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases
por: Yamashita, Shizuya, et al.
Publicado: (2020)

PARP9 and PARP14 cross-regulate macrophage activation via STAT1 ADP-ribosylation
por: Iwata, Hiroshi, et al.
Publicado: (2016)

Effect of pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor α modular (SPPARMα), in atherosclerosis model using low density lipoprotein receptor knock-out swine with balloon injury
por: Konishi, Hirokazu, et al.
Publicado: (2020)

Synergizing Light and Machine Learning to Comprehensively Reveal Coronary Plaque Composition
por: Osborn, Eric A., et al.
Publicado: (2021)

A novel selective PPARα modulator, pemafibrate promotes ischemia-induced revascularization through the eNOS-dependent mechanisms
por: Kawanishi, Hiroshi, et al.
Publicado: (2020)

Pemafibrate, a selective PPARα modulator, prevents non-alcoholic steatohepatitis development without reducing the hepatic triglyceride content
por: Sasaki, Yusuke, et al.
Publicado: (2020)

Medial and Intimal Calcification in Chronic Kidney Disease: Stressing the Contributions
por: Rogers, Maximillian, et al.
Publicado: (2013)

Editorial: Exploring the Frontiers of Regenerative Cardiovascular Medicine
por: Phillippi, Julie A., et al.
Publicado: (2019)

Peroxisome Proliferator-Activated Receptor α (PPARα) down-regulation in cystic fibrosis lymphocytes
por: Reynders, Veerle, et al.
Publicado: (2006)

Examination of Ligand-Dependent Coactivator Recruitment by Peroxisome Proliferator-Activated Receptor-α (PPARα)
por: Tien, Eric S., et al.
Publicado: (2006)

Cellular Heterogeneity of Activated Primary Human Macrophages and Associated Drug–Gene Networks: From Biology to Precision Therapeutics
por: Decano, Julius L., et al.
Publicado: (2023)

Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia
por: Fruchart, Jean-Charles
Publicado: (2017)

Carnitine regulates myocardial metabolism by Peroxisome Proliferator-Activated Receptor-α (PPARα) in alcoholic cardiomyopathy
por: Jing, Ling, et al.
Publicado: (2011)

Peroxisome proliferator-activated receptor-α (PPARα) regulates wound healing and mitochondrial metabolism in the cornea
por: Liang, Wentao, et al.
Publicado: (2023)

Selective peroxisome proliferator-activated receptorα modulators (SPPARMα): The next generation of peroxisome proliferator-activated receptor α-agonists
por: Fruchart, Jean-Charles
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_0j00i70rbma1frpsomp0jvitr0